04/13/2016
https://congress.gov...
"I believe that there are many factors to encouraging and ensuring robust investment in medicines."
"There clearly needs to be some balance between the exclusivity and the cost savings."
"I seriously question whether a lengthy exclusivity will achieve the kind of savings we all hope to see."
"And the problem I have is if we grant exclusivity, we are essentially giving the pharmaceutical free rein to charge whatever it wants during that time period."